Publication | Closed Access
Efficacy and safety of apremilast for 3 months in Behçet’s disease: A prospective observational study
14
Citations
12
References
2020
Year
Significant improvement in oral ulcer and BDCAF with apremilast was confirmed in real-world BD patients after 3 months. The combination of colchicine and apremilast appears to be well tolerated in BD in the short-term.
| Year | Citations | |
|---|---|---|
Page 1
Page 1